Apellis focuses on complement system inhibition at the C3 level (the central protein in the complement cascade) for rare disease treatment. The company has achieved GAAP profitability after years of R&D spending, with EPS rising 116% in the last year—an important inflection point for a growth-stage biotech.
Cyborg Score Rationale
Apellis achieved 42% revenue growth over the past year with average 127% yearly growth over recent years, reflecting strong product launches. The company recently beat Q4 earnings estimates with $0.47 EPS vs. consensus of ($0.39), though analyst sentiment remains mixed due to competitive and execution risks.
Top Insights
SYFOVRE generated $587M in 2025 net product revenue, driving 42% total revenue growth
EMPAVELI showed very strong launch momentum in C3G/IC-MPGN with expectations of 50% market penetration at peak (~5,000 patient epidemiology)
Pivotal trials initiated for focal segmental glomerulosclerosis (FSGS) and delayed graft function (DGF), rare kidney diseases with significant unmet need
Company ended 2025 with $466M cash and is on path to profitability, addressing a $94M convertible note maturity in September 2026
Named Competitors
Other complement C3 inhibitors — Alternative C3-targeting therapies in development
Anti-VEGF and other GA therapies — Competing ophthalmology treatments for geographic atrophy
Kidney disease therapeutics — Competing treatments for C3G, IC-MPGN, and FSGS
Recent Developments
(February 2026) Q4 2025 earnings beat; 5-year geographic atrophy data to be presented at Macula Society Annual Meeting
(February 2026) European Commission approved Aspaveli for C3G/IC-MPGN, triggering $25M milestone payment from partner Sobi
(January 2026) Phase 2 combination study of SYFOVRE + APL-3007 ongoing; topline data expected in 2027
(2026) Prefilled syringe clinical study complete; regulatory submission planned for H1 2026
Open the full interactive Apellis Pharmaceuticals, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.